Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 253

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 253
---
 has substantial experience in rapidly progressing new drugs to clinical proof of concept, completing successful pivotal registration programs and successfully 
 commercializing products.                                                                                                                                                                                                                              |

We believe that our innovative non-opioidproduct portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients’ lives. Our Management Team We have assembled a management team of experienced biopharma industry veterans, who have deep scientific, business and leadership expertise in the pharmaceutical industry, as well as strong transactional and business development track records. Our management team is led by our Chief Executive Officer, President and Chairperson, Henry Ji, Ph.D, who has over 20 years of global biopharmaceutical and biotechnology experience. Dr. Henry Ji is the holder of several issued and pending patents in the life science research field. Our Chief Financial Officer, Stephen Ma, has more than 15 years of finance and operational expertise across pharmaceuticals and venture-backed biotechnology companies. Our research efforts are guided by highly experienced scientists and experts. Our management team contributes a diverse range of experiences from leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. With this leadership, we believe we are well positioned to achieve our vision of becoming the leading pain management company delivering novel non-opioidand non-addictivetreatments aiming to provide safe, effective and durable relief of multiple pain conditions. 169

In addition, we are supported by impressive teams across all levels of the organization. We
hire and develop world-class talent from diverse backgrounds in biopharma, academia, technology and finance to ensure we have all of the capabilities to design and deliver first-class pain management therapies.

Our Product Portfolio

ZTlido

Our marketed product, ZTlido, is a lidocaine topical system approved for the relief of neuropathic pain associated with PHN. ZTlido was
strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.
We launched ZTlido in October 2018 with an integrated commercial organization and we believe its differentiated therapeutic profile, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will
continue to drive, accelerated sales growth and